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§Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942 Al-Kharj, Saudi Arabia
⊥Department of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, 35430 Urla-Izmir, Turkey
*S Supporting Information
ABSTRACT: Biotransformation of neoruscogenin (NR, 1,
spirosta-5,25(27)-diene-1β,3β-diol), the major bioactive sap-
ogenin of Ruscus preparations, was carried out with the
endophytic fungus Alternaria eureka. Fourteen new biotrans-
formation products (2−15) were isolated, and their structures
were elucidated by NMR and HRESIMS data analyses. A.
eureka affected mainly oxygenation, oxidation, and epoxidation
reactions on the B and C rings of the sapogenin to afford
compounds 8−15. In addition to these, cleavage of the
spiroketal system as in compounds 2−7 and subsequent
transformations provided unusual metabolites. This is the first
study reporting conversion of the spirostanol skeleton to cholestane-type metabolites 2−5. Additionally, the cleavage of the C-
22/C-26 oxygen bridge yielding a furostanol-type steroidal framework and subsequent formation of the epoxy bridge between C-
18 and C-22 in 7 was encountered for the first time in steroid chemistry.
The natural product drug discovery process involvesisolation of new metabolites from natural sources,
investigation of their biological activities, and semisynthesis of
more active analogues. Compared to chemical methods
microbial biotransformation is advantageous for preparing
new oxygenated steroid derivatives due to the stereo- and
regioselective reaction capability and its operation under mild
conditions.1−4 In addition to overcoming the problems
confronted in chemical synthesis, this process can be of
assistance to establish biosynthetic pathways, increase/decrease
the bioactivity/toxicity profiles of the lead molecules, or
support structure−activity relationship studies. Moreover, it is
a useful method to predict drug metabolism due to the
similarity of the enzyme systems of fungi and mammalians.5,6
Endophytic organisms are bacterial or fungal microorganisms
that colonize internal tissues of living plants without causing
any disease symptoms, and they constitute one of the most
exciting groups of microorganisms. They have attracted a great
deal of attention due to their ability to produce novel bioactive
secondary metabolites for many years.7−9 While producing
interesting chemistry, they are also able to interact with their
hosts via special enzymes and chemicals, which make them
useful sources as biocatalysts.10−15
Neoruscogenin (NR, 1) is one of the major spirostanol
steroids of Ruscus aculeatus (Butcher’s broom, Rusci rhizome,
Asparagaceae). The powdered roots, extracts, and the mixture
of the major bioactive steroidal sapogenins ruscogenins
[mixture of two major sapogenins, viz., neoruscogenin (1)
and ruscogenin] are components of various pharmaceutical
preparations to treat chronic venous insufficiency, varicose
veins, hemorrhoids, and orthostatic hypotension due to their
pharmacological activities.16−24 The European Pharmacopoeia
prescribes “not less than 1.0% of total sapogenins expressed as
ruscogenins (neoruscogenin and ruscogenin mixture)”, and the
European Scientific Cooperative on Phytotherapy recommends
oral use of 7−11 mg/day.25,26
Despite several reported semisynthesis and biotransforma-
tion studies of steroids, studies performed on ruscogenin have
so far been limited,27−30 and there has been neither an in vitro
nor in vivo report on NR revealing its metabolic fate. In order
to shed light into the metabolism of neoruscogenin (1),
estimate its likely mammalian metabolites, and investigate the
potential use of endophytes as biocatalyst, we herein report
biotransformation of NR by the endophytic fungus Alternaria
eureka. As a result, 14 biotransformation products (2−15) were
purified from the biotransformation broth by extensive
chromatographic procedures. The structures of the metabolites
were elucidated by NMR and HRESIMS data analyses. A.
eureka affected mainly the anticipated oxygenation, oxidation,
and epoxidation reactions to afford compounds 8−15, whereas
cleavage of the spiroketal system resulted in exceptional
transformation products 2−7.
Received: November 8, 2017
Published: June 12, 2018
Article
pubs.acs.org/jnpCite This: J. Nat. Prod. 2018, 81, 1357−1367
© 2018 American Chemical Society and
American Society of Pharmacognosy 1357 DOI: 10.1021/acs.jnatprod.7b00898
J. Nat. Prod. 2018, 81, 1357−1367
D
ow
nl
oa
de
d 
vi
a 
IZ
M
IR
 Y
U
K
SE
K
 T
EK
N
O
LO
JI
 E
N
ST
IT
U
SU
 o
n 
Ja
nu
ar
y 
17
, 2
02
0 
at
 0
7:
34
:5
1 
(U
TC
).
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
.
■ RESULTS AND DISCUSSION
The literature survey and preliminary screening studies have
prompted the use of the endophytic fungus A. eureka as
biocatalyst to transform the steroidal sapogenin neoruscogenin
(1). After 10 days of incubation, 14 metabolites (2−15)
(Figures 1 and 2) were isolated from the broth, and the
structures were elucidated by means of 1D and 2D NMR and
HRMS experiments. The 1H and 13C NMR spectroscopic data
of the compounds are collated in Tables 1−3.
The sodium adduct ion at m/z 499.2653 [M + Na]+ (calcd
499.2671 for C27H40O7Na) in the HRESIMS spectrum of 2
Figure 1. Structures and yields of the cholestane- (2−6) and furostanol-type (7) biotransformation products.
Figure 2. Structures and yields of the spirostanol-type biotransformation products (8−15).
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indicated eight indices of hydrogen deficiency, a 48 amu
increase over 1. The 13C NMR and DEPT135 spectra showed
two carbonyl signals at δC 212.9 and 220.1, two resonances of a
disubstituted olefinic system (δC 108.3, t; 150.1, s), and signals
of a trisubstituted olefinic system (δC 131.0, d; 140.2, s) that
revealed a tetracyclic framework for 2, suggesting ring
cleavage(s). Based on the absence of the characteristic
spiroketal carbon resonance (C-22, ca. 110 ppm) and the
characteristic H-16 signal, the low-field shift of the exocyclic
H2-27 resonances (ca. 0.5 ppm), and replacement of the
characteristic AB-system signal of H2-26 with an oxymethylene
singlet, the aforementioned cleavage was evident. Thus, it was
inferred that the spirostanol skeleton was transformed into a
steroidal derivative with an acyclic side chain. The DEPT-135,
13C NMR, and HSQC spectra showed two additional low-field
signals at δC 78.4 (s) and 66.7 (d). The former carbon
displayed a long-range HMBC cross-peak with an exchangeable
proton resonating at δH 6.48 (Figure 3), indicative of
hydroxylation of a methine carbon of 1. Examination of the
COSY and TOCSY spectra led to identification of five main
spin systems (SS1−SS5) in 2. One of these spin systems, SS-2
[H-6 → H-7(O) → H-8 → H-9 → H2-11 → H2-12], located
one of the hydroxy groups at C-7. The deshielding of H-7 (δH
4.96) due to the Δ5(6) double bond was also noteworthy. The
simplified H-17 spin system evident in the COSY spectrum and
the 1.00 ppm deshielding of H-17 (δΗ 3.92, d, J = 11.0 Hz)
compared to 1 implied the presence of a carbonyl group at C-
16. In the HMBC spectrum, the carbonyl resonating at δC
220.1 (C-16) displayed correlations with H-17 and protons of a
methylene group (H2-15) resonating as an AB system (δH 3.20
and 3.05, both d, JAB = 18.5 Hz). The isolated C-15 methylene
protons indicated functionalization at C-14. The HMBC
correlation of the carbon at δC 78.4 (s) and H3-18 defined
the location of the second hydroxy group at C-14. The spin
systems and their interconnectivities secured by the 2D NMR
spectra permitted establishment of the tetracyclic skeleton from
C-1 to C-21. The aforementioned conclusions left the C-22 →
C-27 system to be identified. The HMBC correlation of the
second carbonyl signal (δC 212.9) with H3-21 (δH 1.08, d, J =
5.5 Hz) and H-20 (δH 2.80) verified that C-22 was also
oxygenated after cleavage of the spiroketal system to produce
the C-22 carbonyl group. Inspection of the COSY spectrum
revealed another spin system (SS-4) including two methylene
groups, which was readily assigned to H2-23 and H2-24 based
Table 1. 1H and 13C NMR Data of Compounds (2−6) (500 MHz, in Pyridine-d5)
2 3 4 5 6
position δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz)
1 77.2 3.84 d (11.5) 77.5 3.82 m 76.2 3.83 m 76.2 3.87 d (11.0) 72.5 4.27 ddd (5.5,
6.0, 6.0)
2 43.7 2.27 m, 2.65 m 42.8 2.24 ddd (11.5, 12.0,
12.0), 2.53 m
42.9 2.27 dd (11.5, 12.0),
2.62 m
43.4 2.29 ddd (11.5, 12.0,
12.0), 2.65 m
44.9 2.99 m,
3.05 m
3 67.7 3.95 m 67.3 3.84 m 66.1 3.93 m 66.0 3.91 m 197.7
4 43.6 2.70 m 43.7 2.74−2.78 m 43.6 2.76 m 43.6 2.75 m 124.3 5.93 s
5 140.2 143.9 166.0 166.2 162.8
6 131.0 5.97 s 126.1 5.93 d (4.5) 128.2 6.04 s 128.2 6.03 s 130.1 6.30 dd (1.0,
9.5)
7 66.7 4.96 bs 66.1 4.32 s 200.1 200.5 140.1 6.25 dd (1.0,
9.5)
8 43.6 2.27 m 37.9 1.95 m 48.3 2.87 m 48.3 2.86 m 41.3 2.89 m
9 42.9 2.55 ddd (5.0,
5.0, 11.5)
38.2 2.77 m 44.8 2.94 m 44.8 2.94 m 44.7 2.61 m
10 43.2 44.1 44.8 44.8 42.4
11 22.9 1.95 m, 2.99 m 22.7 1.93 m, 2.92 m 23.0 1.99 ddd (13.0, 12.0,
12.5), 2.92 m
23.1 1.99 m, 2.92 m 23.3 1.99 m,
2.55 m
12 31.4 1.70 d (12.0),
2.67 m
31.4 1.60 m, 2.72 m 30.9 1.68 d (12.5),
2.62 m
30.8 1.67 m, 2.61 m 31.5 1.70 m,
2.53 m
13 46.1 46.0 46.6 45.6 46.0
14 78.4 79.7 77.1 77.1 78.6
15 49.8 3.20 d (18.5),
3.05 d (18.5)
47.5 2.49 d (17.5), 2.64 d
(17.5)
49.2 2.75 m, 3.59 d
(19.2)
49.2 3.57 m 46.3 2.60 m,
2.75 m
16 220.1 218.7 219.3 219.4 217.9
17 60.2 3.92 d (11.0) 60.7 3.89 d (11.0) 59.5 3.87 d (11.0) 59.6 3.87 d (11.0) 60.6 3.94 d (13.0)
18 16.6 1.07 s 16.3 1.00 s 16.9 1.01 s 17.2 1.02 s 17.2 1.07 s
19 13.4 1.41 s 12.9 1.37 s 12.1 1.50 s 12.1 1.50 s 11.4 1.40 s
20 43.7 2.80 m 43.4 2.75 m 43.4 2.74 m 43.5 2.77 m 43.7 2.80 m
21 15.7 1.08 d (5.5) 15.6 1.05 d (7.0) 15.6 1.06 d (5.6) 15.3 1.08 d (6.5) 15.5 1.06 d (7.0)
22 212.9 212.6 212.8 212.8 212.5
23 40.8 3.00 m, 3.13 dd
(7.5, 8.5)
40.7 3.00 m, 3.15 m 40.8 2.95 m, 3.16 m 40.3 2.93 m, 3.09 m 40.8 3.00 m,
3.13 m
24 27.0 2.70 m 27.1 2.74 m 27.0 2.72 m 26.9 2.57 m 27.1 2.22 m (2H)
25 150.1 150.2 150.1 144.2 150.2
26 65.2 4.39 s 65.2 4.40 s 65.2 4.39 s 66.9 4.69 s 65.3 4.41 s
27 108.3 5.07 s, 5.42 s 108.2 5.08 s, 5.43 s 108.3 5.43 s, 5.08 s 112.0 5.07 s, 5.13 s 107.9 5.09 s, 5.43 s
COCH3 170.4 2.00 s
COCH3 20.5
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on their 2JH−C and
3JH−C correlations with C-22 (δC 212.9),
respectively. The long-range correlations of the terminal
hydroxymethyl signal at δH 4.39 (s) with the carbon resonances
at δC 150.1 (C-25), 108.3 (C-27), and 27.0 (C-24), and C-24,
C-25 and C-26 to H2-27 (δH 5.07 and 5.42, both s), were of
assistance to deduce the remaining part of the side chain as
shown in Figure 3. The relative configuration was established
via the 2D-ROESY data. The correlation of H-7 with α-oriented
H-9 (δH 2.55, ddd, J = 5.0, 5.0, 11.5 Hz) and the cross-peak
between these two resonances and exchangeable proton signal
at δH 6.48 [C-14(OH)] confirmed the orientation of the OH
groups as 7β and 14α. Thus, the structure of metabolite 2 was
defined as cholesta-5,25(27)-diene-1β,3β,7β,14α,26-pentaol-
16,22-dione.
The molecular formula of metabolite 3 was established as
C27H40O7 based on
13C NMR and HRMS data (obsd [M +
Na]+, m/z 499.2656; calcd 499.2672). While the carbon
resonances are similar, the 1H NMR spectrum of 3 showed two
discrepancies in comparison to 2. When the spin-system
starting from the distinguishing olefinic resonance H-6 was
established, the upfield shift of the oxymethine proton H-7 was
significant, suggesting a configurational difference in metabolite
3 (δΗ 4.96 in 2, δΗ 4.32 in 3). As a result of this configurational
change, the H2-15 resonances were also affected (δΗ 3.20 and
3.05 in 2, δΗ 2.64 and 2.49 in 3), signifying an intramolecular
hydrogen bond between the C-14 and C-7 hydroxy groups.
The orientational difference of C-7(OH) was further supported
by the ROESY spectrum. The cross-peak from β-oriented H-8
(δΗ 1.95) to H-7 (δΗ 4.32) and from α-oriented H-9 (δΗ 2.77)
to the exchangeable proton of C-14(OH) (δΗ 6.48) confirmed
α cofacial orientations of C-7(OH) and C-14(OH). On the
basis of these findings, the structure of compound 3 was
defined as cholesta-5,25(27)-diene-1β,3β,7α,14α,26-pentaol-
16,22-dione.
The HRMS spectrum of metabolite 4 showed a major ion
peak at m/z 497.2532 (calcd for C27H38O7Na 497.2512),
indicating a molecular formula of C27H38O7 with nine indices of
hydrogen deficiency. The 1H and 13C NMR spectra of 4 were
similar to those of 2 and 3, except the signals deriving from an
additional carbonyl resonance (δC 200.1) and those in its close
proximity. Examination of the 1D and 2D NMR spectra of 4
permitted establishment of the additional carbonyl group at C-
7. The correlation of H-15α, which was deduced by the cross-
peak from H-15ax to Me-18β, and exchangeable proton of C-
14(OH) (δH 6.39) in the ROESY spectrum revealed the
orientation of the hydroxy group at C-14 to be α.
Consequently, the structure of metabolite 4 was defined as
cholesta-5,25(27)-diene-1β,3β,14α,26-tetraol-7,16,22-trione.
The molecular formula of 5 was determined as C29H40O8
based on the major ion peak at m/z 555.2377 [M + K]+ (calcd
Table 2. 1H and 13C NMR Data of Compounds 7−11 (500 MHz, in Pyridine-d5)
7 8 9 10 11
position δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz)
1 77.6 3.83 d (8.5) 77.5 3.82 dd (3.5, 11.5) 77.5 3.80 dd (4.0,
11.5)
77.5 3.84 m 77.4 3.83 m
2 43.0 2.23 m, 2.55 m 43.1 2.55 m, 2.23 ddd
(12, 11.5, 11.5)
42.9 2.23 m, 2.51 m 42.8 2.24 m, 2.53 m 42.7 2.25 m, 2.55 m
3 67.4 3.89 m 67.4 3.89 m 67.3 3.83 m 67.3 3.84 m 67.4 3.89 m
4 43.5 2.70 m 43.6 2.70 m 43.6 2.75 m 43.4 2.70 m 43.5 2.72 m
5 142.9 143.1 143.7 143.7 143.0
6 127.8 6.04 d (5.0) 128.0 6.06 d (5.0) 126.5 5.94 d (5.0) 126.5 5.95 d (5.0) 127.7 6.07 d (5.0)
7 64.3 4.07 s 64.7 4.09 bs 66.3 4.46 s 66.2 4.51 d (12.0) 64.7 4.14 bs
8 38.7 1.77 m 38.5 1.77 m 39.4 2.02 m 38.7 2.07 dd (3.5, 7.5) 37.6 1.77 m
9 43.1 2.14 m 43.6 2.70 m 38.3 2.76 m 38.7 2.87 ddd (5.5,
12.5, 13.0)
42.7 2.35 m
10 44.0 44.1 44.1 44.2 44.3 44.2
11 24.0 1.41 m, 2.97 dd
(3.5, 14.0)
23.9 1.83 m, 2.90 m 23.1 1.93 m, 2.92 m 33.6 2.14 m, 3.36 m 34.1 2.10 m, 3.34 m
12 37.4 1.31 m, 1.88 m 40.2 1.33 m, 1.77 m 32.4 1.42 m, 2.51 m 72.4 4.96 dd (5.0,
11.6)
79.2 3.80 m
13 45.2 39.9 44.5 49.7 45.5
14 48.3 2.11 m 50.2 2.10 m 87.5 89.7 49.0 2.17 m
15 36.8 2.69 m, 1.83 m 32.1 1.61 m, 2.55 m 40.8 2.04 m, 2.62 m 41.2 2.20 m, 2.66 m 31.9 1.81 m, 2.65 m
16 80.5 4.64 m 81.5 4.61 ddd (7.5, 11.5,
12.5)
82.2 5.12 ddd (6.5,
7.0, 7.5)
82.4 5.22 ddd (6.0,
7.5, 8.0)
81.5 4.69 ddd (7.5,
8.0, 8.5)
17 56.6 1.82 m 63.0 1.88 m 59.5 2.80 m 59.4 3.18 dd (8.0, 7.0) 62.9 2.25 m
18 65.2 3.41 d (11.8), 4.07
d (11.9)
16.4 0.98 s 19.7 1.12 s 13.5 1.37 s 11.1 1.24 s
19 12.5 1.26 s 12.7 1.34 s 13.0 1.36 s 13.0 1.38 s 12.6 1.36 s
20 35.9 2.23 m 41.7 1.99 dd (6.5, 7.0) 41.7 2.10 m 42.6 2.31 m 43.0 2.25 m
21 14.5 0.85 d (6.5) 14.8 1.04 d (7.0) 15.1 1.09 d (7.0) 14.4 1.41 d (6.0) 14.1 1.36 d (6.0)
22 109.9 109.2 109.4 109.8 109.5
23 27.8 2.47 m, 2.61 m 33.0 1.78 m 33.1 1.82 m 33.2 1.87 m 31.9 1.79 m, 2.65 m
24 32.8 2.03 m, 2.23 m 28.7 2.23 m, 2.70 m 28.8 2.25 m, 2.74 m 28.9 2.25 m, 2.77 m 29.8 2.24 m, 2.73 m
25 151.1 144.3 144.3 144.4 144.3
26 65.2 4.43 s 64.3 4.00 d (12.0), 4.40 d
(12.0)
64.7 4.00 d (9.5), 4.47
d (11.5)
64.7 4.05 d (12.0),
4.51 d (12.0)
64.3 4.00 d (12.0),
4.44 d (12.0)
27 107.8 5.04 s, 5.38 s 108.4 4.78 d (9.5) 108.5 4.87 d (9.5) 108.5 4.78 s, 4.81 s 180.4 4.79 s, 4.77 s
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555.2360 for C29H40O8K) in the HRMS spectrum. In the
1H
and 13C NMR spectra of 5, the resonances were almost
superimposable with those of compound 4, except additional
signals originating from an acetyl group [δH 2.00, s; δC 20.5 (q)
and 170.4 (s)]. In the 1H NMR spectrum, the downfield shift
for H2-26 (ca. 0.30 ppm at δH 4.69) and an upfield shift for H2-
27 (ca. 0.30 ppm at δH 5.13) implied the acylation position as
C-26(O). This assumption was substantiated by the long-range
HMBC correlation from the ester carbonyl signal at δC 170.4 to
H2-26a (δH 4.69). Based on the NOE correlations from H-9
and H-17 (δH 2.94 and 3.87, respectively) to the exchangeable
proton, the orientation of C-14(OH) (δH 6.41) was determined
to be α. Thus, the structure of 5 was elucidated as 26-O-
acetylcholesta-5,25(27)-diene-1β,3β,14α,26-tetraol-7,16,22-tri-
one.
The HRESIMS spectrum of 6, exhibited a sodium adduct ion
at m/z 479.2403 [M + Na]+ (calcd 479.2410) and led to
establishment of its molecular formula as C27H36O6 with 10
indices of hydrogen deficiency. In the 1H and 13C NMR spectra
of 6, the signals arising from the rings C and D and the side
Table 3. 1H and 13C NMR Data of Compounds 12−15 (500 MHz, Pyridine-d5)
12 13 14 15
position δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz)
1 75.3 3.93 m 78.3 3.82 d (10.5) 76.2 3.84 m 77.5 4.30 m
2 41.7 2.23 m, 2.70 m 42.4 2.35 m, 2.57 m 43.2 2.25 m, 2.60 m 41.4 2.31 m, 2.58 m
3 67.4 3.88 m 67.0 3.91 m 65.9 3.90 m 65.2 4.17 m
4 43.9 2.70 m 43.6 2.70 m, 2.80 m 43.6 2.75 m 43.4 2.77 m
5 143.2 164.7 165.3 63.4
6 128.7 6.07 d (5.5) 126.2 6.12 s 128.4 6.02 s 64.8 3.41 d (3.2)
7 64.3 4.11 bs 200.8 200.9 68.1 4.75 m
8 38.6 1.77 m 79.0 49.5 2.94 m 36.6 2.47 m
9 49.3 2.32 dd (10.0, 10.5) 47.1 3.18 d (3.5) 45.3 2.84 m 36.3 2.88 m
10 46.4 45.7 44.9 40.8
11 66.2 4.38 d (12.5) 21.0 2.47 ddd (13.5, 13.0, 12.5)
3.25 d (13.0)
23.2 1.99 d (12.5), 2.88 m 24.5 1.76 m, 2.57 m
12 49.7 1.70 t (11.5),
2.51 m
33.7 1.58 d (12.0), 2.38 dd (12.0,
14.5)
31.9 1.44 m, 2.33 m 32.7 1.36 m, 2.33 m
13 40.1 45.6 45.4 44.7
14 48.6 1.92 m 86.5 84.5 88.3
15 31.8 1.57 m, 2.51 m 37.6 2.71 m, 3.42 ddd (7.0, 7.5,
7.5)
41.9 2.24 ddd (11.5, 12.0, 12.5), 3.53 ddd
(7.5, 7.5, 5.5)
40.5 1.92 m, 2.45 m
16 81.6 4.58 ddd (7.5, 7.5,
7.0)
82.2 5.14 m 82.3 5.08 m 82.1 5.06 m
17 62.3 1.93 dd (7.5, 8.0) 58.8 2.82 m 58.2 2.71 m 59.1 2.69 m
18 16.8 0.95 s 21.0 1.74 s 20.3 1.13 s 20.0 1.04 s
19 12.3 1.41 s 14.3 1.90 s 12.1 1.46 s 11.1 1.55 s
20 41.7 1.97 dd (7.5, 7.5) 40.6 2.17 m 41.7 2.23 m 41.5 2.04 dd (7.0, 8.0)
21 14.7 1.01 d (6.5) 15.2 1.12 d (7.0) 15.2 1.11 d (7.0) 20.5 1.05 d (9.0)
22 109.3 109.6 109.6 109.5
23 32.9 1.76 m 33.1 1.76 m, 1.80 m 33.1 1.79 m 33.1 1.78 m
24 28.8 2.23 m, 2.70 m 28.7 2.15 m, 2.60 m 29.5 2.21 m, 2.70 m 28.8 2.25 m, 2.70 m
25 144.7 144.3 144.5 144.3
26 64.9 3.98 d (12.5), 4.38 d
(12.5)
64.6 3.96 d (12.5), 4.40 d (12.0) 64.7 4.41 d (12.0), 3.95 d (12.0), 64.7 4.43 d (12.0), 3.99 d
(12.0)
27 109.3 4.79 s, 4.77 s 108.4 4.71 s, 4.74 s 108.4 4.75 d (8.5) 108.5 4.77 d (10.0)
Figure 3. HMBC and COSY correlations of 2, 6, 7, 8, and 15.
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chain were similar to those of compounds 2−5, accounting for
five indices of hydrogen deficiency. Inspection of the 1D and
2D NMR spectra revealed an additional carbonyl group (δC
197.7) together with a trisubstituted (δC 124.3, 162.7, and δH
5.93) and a disubstituted (δC 130.1, 140.1; δH, 6.30, 6.25,
respectively) double-bond system. The oxymethine resonance
at δC 72.5 was readily assigned to C-1 based on its long-range
correlation with H3-19 (δH 1.40). In the COSY spectrum, the
H-1 (δH 4.27) resonance was correlating with a methylene
group (δH 2.99 and 3.05, H2-2), which in turn had no further
cross-peaks. In the HMBC spectrum, the 2JC−H correlation
between the carbonyl signal at 197.7 ppm (C-3) and δH 2.99/
3.05 (H2-2) protons verified an oxidation at C-3 to give a 3-
carbonyl group in 6. The trisubstituted olefinic system was
located at C-4(5) (δC 124.3 and 162.7, respectively) on the
basis of the deshielding of C-5 due to the α,β-unsaturated
carbonyl functionality and key HMBCs from C-2 (δC 44.9) and
C-10 (δC 42.4) to H-4 (δH 5.93) and from C-5 (δC 162.8) to
H3-19 (δH 1.40). Thus, the disubstituted double-bond
resonances (δH 6.25, dd, J = 9.5, 1.0 Hz; δH 6.31, dd, J = 9.5,
2.0 Hz; δC 130.1 and 140.1, respectively) were directly assigned
to C(H)-6 and C(H)-7 (Figure 3). Consequently, the structure
of 6 was determined as cholesta-4,6,25(27)-triene-1β,14α,26-
triol-3,16,22-trione.
The HRMS spectrum of metabolite 7 provided a sodiated
ion peak at m/z 483.2784 [M + Na]+ (calcd 483.2723 for
C27H40O6Na), indicating eight indices of hydrogen deficiency
and a 32 amu increase over 1. In the 1H NMR spectrum of 7,
the resonance of one of the tertiary methyl groups was absent,
and an isolated oxymethylene group was evident from the 1H
and 13C NMR and HSQC spectra as an AB system (δH 4.07, d,
J = 11.9 Hz; δH 3.41, d, J = 11.8 Hz; δC 65.2, t). Examination of
the COSY and TOCSY spectrum starting from the character-
istic resonances, namely, oxymethine proton H-1 and olefinic
H-6, permitted the location of the two major spin systems in
the steroid framework (Figure 3) and revealed an oxygenation
at C-7 (δC 64.3; δH 4.07) as in metabolites 2 and 3.
Furthermore, the new oxymethylene group was attributed to
CH2-18 based on the key HMBCs from C-17 and C-14 to H2-
18 (δ 4.07 and 3.41). Interestingly, in the COSY spectrum, H-
17 did not couple with H-20, which in turn correlated with
CH3-21, suggesting a ca. 90° dihedral angle between H-17 and
H-20. In addition, the third spin system was tracked from the
characteristic H2-27 signals (δH 5.04 and 5.38) through allylic
couplings to the hydroxymethyl H2-26 (δH 4.43, 2H) and H2-
24 (δH 2.03 and 2.23); the latter in turn coupled with H2-23
(δH 2.47 and 2.61). The diastereotopic nature of H2-26,
resonating as a 2H broad singlet, and carbon chemical shifts of
C-25 (δC 151.1) and C-27 (δC 107.8) demonstrated cleavage of
the C-22/C-26 oxygen bridge to afford an acyclic side chain.
The carbon resonance observed at δC 109.9 was assigned to C-
22 based on the 3JC−H correlations from this carbon to H-16,
H-17, H3-21, and H2-24 in the HMBC spectrum. The
correlation between H-16 and C-22 verified the oxygen bridge
(Figure 3), suggesting a furostanol-type framework for
metabolite 7. While all of the structural components accounted
for seven out of eight indices of hydrogen deficiency, the
absence of an additional multiple bond in the structure implied
a recyclization. This assumption was substantiated by the long-
range HMBC correlation between one of the H2-18 protons
(δH 4.07) and C-22 (δC 109.9), revealing epoxy bridge
formation and thus the acetal character of C-22. This six-
membered ring system, which forced the H-16/C-16/C-20/H-
20 system to adopt a dihedral angle of 82° [see MM2-
minimized energy conformer of 7 (Figure 4)], also explained
the absence of coupling between H-17 and H-21. The α-
orientation of the hydroxy group at C-7 was deduced via the
correlation of β-oriented H-8 (δH 1.77) and H-7 (δH 4.07) in
the NOESY spectrum. Thus, the structure of metabolite 7 was
established as 18(22)-epoxyfurosta-5,25(27)-diene-
1β,3β,7α,26-tetraol.
The HRMS data of metabolite 8 exhibited a protonated
molecular ion at m/z 445.2956 [M + H]+ (calcd for C27H41O5
445.2954), revealing a 16 amu increase over NR (1). In the
low-field region of the 1H NMR spectrum, an additional low-
field proton at δH 4.09 was observed. Furthermore, deshielding
of the characteristic olefinic resonance of H-6 (δH 6.06, d, J =
5.0 Hz) inferred an adjacent oxygenation. The significant
COSY correlation between the resonance at δH 4.09 (H-7) and
H-6 (δH 6.06) implied the position of functionalization as C-7
(Figure 3). The long-range correlations of C-5 (δC 143.1) and
C-6 (δC 128.0) with this oxymethine proton also substantiated
the proposed modification. The α-orientation of C-7(OH) was
established via the ROESY cross-peak between H-8 (δH 1.77)
and H-7. Based on these findings, the structure of 8 was
determined as spirost-5,25(27)-diene-1β,3β,7β-triol.
In the HRMS spectrum of 9, a sodium adduct ion was
observed at m/z 483.2733 [M + Na]+ (calcd for C27H40O6Na
483.2723), signifying the presence of two hydroxy groups due
to the 32 amu increase compared to 1. Inspection of the 1H
NMR spectrum of 9 revealed an additional low-field signal at
δH 4.46, whereas a new oxymethine carbon resonance at δC
66.3 was noted in the 13C NMR and DEPT135 spectra together
with an oxygenated tertiary carbon at δC 87.5. The correlation
between H-6 (δH 5.94, d, J = 5.0 Hz) and the new signal
resonating at δH 4.46 verified the first oxygenation at C-7, as in
compound 8. The long-distance correlations between the
tertiary carbon at δC 87.5 and H3-18 (δH 1.12), H-8 (δH 2.02),
and H2-15a (δH 2.62) in the HMBC spectrum verified an
oxygenation at C-14. In the ROESY spectrum, correlation of H-
7 (δH 4.46) with β-oriented H-8 (δH 2.02) and a cross-peak
between the exchangeable proton signal of 14-OH at δH 6.18
and H-17α (δH 2.80) revealed the α-orientations of the hydroxy
groups. Consequently, the structure of metabolite 9 was
defined as spirosta-5,25(27)-diene-1β,3β,7α,14α-tetraol.
The molecular formula of 10 was determined to be C27H40O7
based on the protonated molecular ion at m/z 477.2848 [M +
H]+ (calcd for C27H41O7 477.2858), and the 48 amu difference
in comparison to 1 suggested a trihydroxy analogue.
Examination of the 1D and 2D NMR spectra revealed that
Figure 4. MM2 energy minimized conformer of 7.
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the first two oxygenation positions were C-7 and C-14 as in 9.
The remaining oxymethine resonance at δC 72.4 displayed a
strong 3JC−H correlation with the methyl signal of H3-18 (δH
1.37), substantiating the other oxygenation position at C-12.
From the ROESY spectrum, the α-oriented hydroxy group at
C-7 was readily deduced via the correlation of β-oriented H-8
(δH 2.07) and H-7 (δH 4.52), whereas C-12(OH) was assigned
a β-orientation due to the cross-peak between H-17α (δH 3.18)
and H-12 (δH 4.96). Furthermore, the orientation of C-
14(OH) was inferred from the correlation of the exchangeable
proton (δH 6.16) with H-15a (δH 2.66), which in turn had a
correlation with H-16α (δH 5.22, ddd, J = 7.5, 7.5, 6.0 Hz).
Consequently, the structure of 10 was elucidated as spirost-
5,25(27)-diene-1β,3β,7α,12β,14α-pentaol.
The HRMS spectrum of metabolite 11 provided a
protonated molecular ion at m/z 461.2904 [M + H]+ (calcd
for C27H41O6 461.2903), indicating a 32 amu increase over NR
(1). Two additional low-field oxymethine resonances at δC 79.2
and 64.7 deduced from the 13C NMR and DEPT135 spectra
suggested two sites of oxygenation. The first location was
evident from the COSY correlation from the olefinic H-6 (δH
6.07) to H-7 (δH 4.14), whereas the key long-range correlation
between the new oxymethine carbon resonance at δC 79.2 and
characteristic H3-18 (δH 1.24) together with the spin system
tracked from H-6 to H-12 justified the position of the second
hydroxy group at C-12 as in 10. The ROESY correlation of H-
12 with H-17α (δH 2.25) and a cross-peak between H-7 (δH
4.14) and H-8β (δH 1.77) revealed the orientations of the OH
groups as β and α, respectively. Thus, the structure of
metabolite 11 was elucidated as spirosta-5,25(27)diene-
1β,3β,7α,12β-tetraol.
The HRMS data of metabolite 12 exhibited a protonated
molecular ion at m/z [M + H]+ 461.2901 (calcd for C27H41O6
461.2903), revealing a 32 amu increase over 1. Together with
the characteristic signals of NR (1) an additional low-field
resonance at δH 4.11 was observed in the
1H NMR spectrum,
whereas 13C NMR and DEPT135 spectra revealed two
additional oxymethine signals, suggesting a dihydroxy analogue
of 1. From the characteristic methyl doublet (H3-21: δH 1.01, d,
J = 6.5 Hz) and H-6 olefinic resonance (δH 6.07, d, J = 5.5)
(Table 3), the spin system and its corresponding carbons
constituting the B, C, D, and E rings were deduced using the
COSY, TOCSY, and HSQC spectra and revealed oxygenation
sites as C-7 and C-11. The key HMBCs from C-11 (δC 66.2) to
H-12a (δH 2.51) and H-9 (δH 2.32, dd, J = 10.0, 10.5) and from
C-6 (δC 128.7) and C-8 (δC 38.6) to H-7 (δH 4.11) also
supported these findings. Observation of the cross-peaks
between H-11 (δH 4.38, d, J = 12.5 Hz) and H3-18β (δH
0.95) and H3-19 (δH 1.41) and between H-7 (δH 4.11) to H-8
(δH 1.77) substantiated α-cofacial orientations of both HO-11
and HO-12. Based on these findings, the structure of 12 was
defined as spirosta-5,25(27)-diene-1β,3β,7α,11α-tetraol.
The HRMS spectrum of metabolite 13 provided a
protonated molecular ion at m/z 475.2704 [M + H]+,
supporting the molecular formula of C27H39O7 (calcd for
C27H40O7 475.2696). An α,β-unsaturated carbonyl functionality
(δC 200.8, 164.7, and 126.2) similar to those of 4 and 5 was
evident from the 13C NMR spectrum of 13. This system was
attributed to C-5C-6−C-7(O) on the basis of the long-
range HMBC correlations from C-5 to H3-19 (δH 1.90) and
from C-4/C-10 to H-6. Other distinguishing features observed
for metabolite 13 were the presence of two oxygenated tertiary
carbon resonances (δC 79.0, 86.5) in the
13C NMR spectrum.
When the COSY and TOCSY spectra were inspected
beginning from the H2-12 resonances (δH 1.58 and 2.38), the
spin system H2-12 → H2-11 (δH 2.47 and 3.25) → H-9 (δH
3.18) was established, suggesting the first oxygenation at C-8
due to the absence of correlation between H-9 and H-8.
Moreover, the long-range correlation from the carbon at δC
79.0 to H-6 (δH 6.12) confirmed oxygenation at C-8. The
second hydroxy group was located at C-14 as in 9 and 10
because of the significant HMBCs from the carbon resonating
at δC 86.5 signal to H3-18 (δH 1.74) and H2-15 (δH 2.71 and
3.42). The exchangeable proton of C-8(OH) (δH 7.41) showed
ROESY cross-peaks with H3-18 and H3-19, revealing its β-
orientation, whereas the C-14(OH) proton (δH 4.92) had
correlations with H-9 (δH 3.18) and H-17 (δH 2.82),
substantiating its α-orientation as in 9 and 10. Consequently,
the structure of metabolite 13 was defined as spirosta-5,25(27)-
diene-1β,3β,8β,14α-tetraol-7-one.
In the HRMS spectrum of 14, a sodium adduct ion was
observed at m/z 481.2575 [M + Na]+ (calcd 481.2566 for
C27H38O6Na), indicating a 30 amu difference in comparison to
1. Inspection of the 1H and 13C NMR spectra of 14 suggested
an α,β-unsaturated carbonyl moiety as in 13 (δC 165.3, 128.4,
and 200.9; δH‑6 6.02), which was also corroborated via key
HMBC correlations. Examination of the 13C and DEPT135
spectra indicated an additional carbon signal at δC 84.5. A long-
range correlation between this carbon and H3-18 (δH 1.13)
suggested oxygenation at C-14 as in 9, 10, and 13. Based on the
ROESY correlations between C-14(OH) and H-16/H-9, the
hydroxy group was α-oriented. Thus, the structure of 14 was
elucidated as spirosta-5,25(27)-diene-1β,3β,14α-triol-7-one.
The molecular formula of 15 was found to be C27H40O6
based on the sodium adduct ion at m/z 483.2728 [M + Na]+
(calcd for C27H40O6Na 483.2723), indicating eight indices of
hydrogen deficiency. In the low-field region of the 1H and 13C
NMR spectra, the absence of characteristic resonances (C-5, C-
6 and H-6) derived from the olefinic system was noted. Based
on the absence of unsaturation in 15, an additional ring system
was proposed based on the identical hydrogen deficiency index
compared to NR (1). The major spin systems were established
by COSY and TOCSY spectra, which suggested modifications
in rings B and C. The oxygenation at C-14 was readily inferred
based on the 3JC−H HMBC correlation between C-14 and H3-
18 (δH 1.04). In the COSY spectrum, the last spin system was
tracked from the characteristic H2-12 (δH 1.36 and 2.33) to the
oxymethine H-7 resonance (δH 4.75). The C-7 hydrogen also
coupled with another low-field signal resonating at δH 3.41,
readily assigned to H-6, hence establishing the spin system from
H2-12 to H-6. In the COSY spectrum, H-7 showed a
correlation with an exchangeable proton at δH 7.92, confirming
the second oxygenation position in the structure (Figure 3).
The carbon observed at δC 63.4 was ascribed to C-5 on the
basis of its key HMBCs to H3-19 (δH 1.55) and H2-4 (δH 2.77,
2H, m). When the high-field shift of C-5 was evaluated together
with the remaining index of hydrogen deficiency, the presence
of an epoxide moiety was evident between C-5 and C-6.31,32
Based on the NOESY cross-peaks between H-7 and H-8β/H-
15β, C-14(OH) (δH 5.61), and H-9α (δH 2.88) and the absence
of correlation between HO-7 and HO-6, C-7 and C-14 (OH)
were α-cofacially oriented, whereas the epoxide ring had β-
orientation. Thus, the structure of metabolite 15 was elucidated
as 5β(6)-epoxyspirost-25(27)-ene-1β,3β,7α,14α-tetraol.
The major steroidal sapogenins of Ruscus sp., neoruscogenin
(1) and ruscogenin, are responsible for vasoconstrictive,
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venotonic, antithrombotic, and anti-inflammatory activ-
ity.18,19,23,33,34 The extracts of the underground part of Ruscus
have been standardized to contain these spirostanol steroids as
a mixture, in which neoruscogenin (1) is the major constituent.
Microbial transformation has been widely used to obtain
pharmacologically active steroids. It is advantageous in
comparison to chemical synthesis due to its capability to
perform stereo- and regioselective reactions at active and
inactive sites of the substrate molecules.4,35−37 The recent
studies have shown that endophytes can be used as biocatalysts
due to their ability to catalyze diverse and unique
reactions.11−13,38,39
Our previous studies revealed the biotransformation capacity
of the filamentous fungi, viz. Cunninghamella blakesleeana and
Glomerella fusarioides, toward triterpenoids.40−42 In this study,
we demonstrated the potential of an endophytic fungus (A.
eureka) as biocatalyst to transform the steroidal sapogenin
neoruscogenin. As a result, 14 new metabolites were obtained,
and their structures were elucidated. Metabolites 8−15 were
mainly transformed via actions of CYP450 monooxygenase
enzymes, resulting in oxygenation reactions (8−12 and 15),
whereas subsequent dehydrogenation reactions provided
carbonyl derivatives (13 and 14). As it was expected from
the literature, the main oxygenation site was C-7 due to its
allylic nature in the B ring.4,43,44 The other oxygenation
location was C-14, which was shown to be subject to
oxygenation as in previous studies with other fungi.45−47
Oxygenations at C-8, C-11, and C-12 were also observed. C-11
and C-12 oxygenations are more common in steroid chemistry;
however, C-8 is at an encumbered position on the steroid
skeleton, and modification of this stereocenter is rare due to
steric hindrance. Based on the literature, only Alternaria
alternata and Corynespora cassiicada CYP450s are capable of
performing this unique oxygenation.48,49
The other striking reaction occurring in compound 1 was
epoxidation at the Δ5(6) olefinic bond to afford 15. Even though
there are several reports of microbial50−53 or semisynthetic54,55
epoxidation products of steroids, this is the first study
demonstrating a Δ5(6) epoxidation on a steroidal skeleton by
a microbial enzyme system.
A spiroketal hydrolysis reaction of 1 afforded the acyclic side
chain of metabolites 2−6 (Figure 5). Subsequently 2−6 are
susceptible to further transformations on the acyclic/choles-
tane-type steroidal framework to give oxygenation, oxidation,
acylation, migration, and dehydration products. Cleavage of the
C-22(O)C-26 oxygen bridge afforded a furostanol-type
skeleton, and its modification resulted in the formation of a
C-18(O)C-22 epoxide ring system (7). These cleavages and
further epoxide ring formation are reported for the first time in
a microbial transformation study. In addition, a spiroketal
hydrolysis reaction is important for the synthesis of potent
cytotoxic metabolites under mild conditions, viz., the
cholestane-type steroid OSW-1 (3β,16β,17α-trihydroxychol-
est-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-β-D-xylopyrano-
syl)-(1→3)-(2-O-acetyl-α-L-arabinopyranoside)).56−59
In summary, the catalytic diversity of the endophytic fungus
A. eureka is remarkable. These results prove the capability of
endophytes for catalyzing novel reactions and warrant further
studies to exploit their use in the field of natural product and
bioorganic chemistry. Finally, as can be seen from the diversity
of the metabolites, neoruscogenin (1), the major bioactive
component of the Ruscus preparations, is subject to many
biotransformation reactions, which might be taken into
consideration for its conceivable mammalian metabolites, as
well as its current or potential therapeutic use.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured using a PerkinElmer 341 polarimeter. MS data were
acquired on an Agilent 1200/6530 Instrument−HRTOFMS. 1D and
2D NMR spectra were obtained at 500 MHz for 1H and 125 MHz for
13C on a Bruker DRX 500 spectrometer, in pyridine-d5, with solvent
peaks used as references. Column chromatography experiments were
carried out on silica gel 60 (40−63 μm-Merck), Sephadex LH-20 (GE
Healthcare), and RP (C18, 25−40 μm) (Merck). TLC analyses were
carried out on silica gel 60 F254 (Merck) and RP-18 F254s (Merck)
plates. HPTLC experiments were carried out on HPTLC silica gel 60
F254 (Merck). Compounds were detected by UV and 20% aqueous
H2SO4 spraying reagent followed by heating at 105 °C for 1−2 min.
Substrate. The substrate neoruscogenin was isolated and purified
from Ruscus aculeatus L., donated by Bionorm Natural Products
Production & Marketing Corp., Menderes-Izmir, Turkey. Its purity
was determined to be 95% by HPLC analysis.
Fungal Strain and Culture Media. The endophytic fungus
Alternaria eureka was isolated from Astragalus angustifolius, collected in
Manisa-Spil Mountain, Izmir, Turkey, in June 2013. It was identified
based on DNA sequence analysis conducted by DSMZ (Leibniz
Institute DSMZ-German Collection of Microorganisms and Cell
Cultures). The original culture was deposited at the Erdal Bedir
Laboratory with the deposit number 20131E1BL1.41 All cultures were
maintained on potato dextrose agar (PDA) slants and stored at 4 °C
Figure 5. Putative mechanism of spiroketal ring cleavage to yield the cholestane-type framework.
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until use. Prior to biotransformation, the fungus was precultivated on
PDA in Petri dishes for 5−7 days at 25 °C.
Microbial Transformation Procedures. The biotransformation
process was conducted at two scales, analytical and preparative.
Inoculum of 2% derived from the suspension of 5−7-day-old cultures
with Tween 80 (0.1%) was used in the biotransformation process. A
one-stage fermentation protocol was followed, where 1 was fed to the
media 72 h after the inoculation. The biotransformation media
contained 2% glucose, 0.5% yeast extract, 0.5% NaCl, 0.5% K2HPO4,
and 0.5% (w/v) peptone (pH 6.0). Analytical scale was conducted
using 250 mL flasks containing 50 mL of media and 1 (10 mg). Every
2 days, samples with a volume of 0.5 mL were taken and centrifuged.
The supernatants were extracted with EtOAc. In order to differentiate
the transformed products from the metabolites of the microorganisms,
one flask was kept under the same conditions but without lead
compound. In preparative scale, 34 Erlenmeyer flasks each containing
200 mL of biotransformation media and 40 mg of 1 were used at the
same conditions as analytical scale (25 °C and 180 rpm) for 10 days.
Extraction and Isolation. After the incubation period, prior to the
extraction with EtOAc (×3) and n-BuOH, microorganisms were
separated from the media by using a Buchner funnel. After drying over
anhydrous Na2SO4, the organic layers were evaporated under reduced
pressure. The EtOAc (1.373 g) and n-BuOH (1.253 g) extracts were
applied to Sephadex LH-20 column chromatography (CC) (100 g, 3.5
× 43 cm) separately and eluted with MeOH. The fractions from each
column with NR metabolites, viz. 19−28 (1.157 g) and 19 and 20
(284.9 mg), were pooled and subjected to reversed-phase silica gel
(C18, 70 g, 3.5 × 26 cm) to yield 39 main fractions after elution with a
MeOH/H2O gradient (30:70 100 mL, 35:65 100 mL, 40:60 100 mL,
45:55 100 mL, 50:50 300 mL, 55:45 200 mL, 60:40 200 mL, 70:30
300 mL, 80:20 300 mL, 90:10 250 mL, 100:0 250 mL). Fraction A
(33.7 mg) was purified on silica gel open-column chromatography (8
g; 2 × 9.5 cm), eluting with CHCl3/MeOH/H2O (90:10:0.5), to
afford 3.5 mg of 2. In order to isolate metabolites 4 (5.1 mg) and 7
(4.6 mg), fraction B (42.3 mg) was subjected to silica gel open-column
chromatography (12 g; 2 × 13 cm) and eluted with CHCl3/MeOH/
H2O (95:5:0.5). Fraction C (63.0 mg) was first purified on silica gel
CC (15 g, 2 × 14 cm) with CHCl3/MeOH/H2O (95:5:0.5) to give 6
(1.5 mg). To isolate metabolite 3 (0.5 mg), subfraction C, C1 (5.5
mg), was subjected to preparative TLC (HPTLC) eluting with n-
hexane/EtOAc/MeOH (10:10:4). To purify metabolite 5, fraction D
(38 mg) was subjected to silica gel CC (12 g, 1.5 × 18 cm) and eluted
with CHCl3/MeOH (95:5). Subfraction D1 (5.5 mg) was subjected to
HPTLC using CHCl3/MeOH/H2O (85:15:0.5). Fractions E and F1
containing the metabolite 10 (9.4 mg) were separately subjected to
silica gel CC. Fraction E (30 mg) was subjected to silica gel CC (10 g,
1.5 × 15 cm) and eluted with CHCl3/MeOH/H2O (90:10:0.5).
Fraction F1 (36.3 mg), the supernatant of fraction F (48.2 mg), was
also subjected to silica gel CC (15 g, 1.5 × 20 cm) eluted with CHCl3/
MeOH (90:10) to which 0.2 μL of HOAc was added for each 100 mL.
Eluting fraction G with cyclohexane/EtOAc/MeOH (10:10:1) on
silica gel CC (8 g, 1.5 × 12 cm) afforded 8.0 mg of metabolite 11.
With further purification of subfraction G (fraction G1) (7.5 mg) on
HPTLC with CHCl3/MeOH/H2O (90:10:0.5), 3.0 mg of metabolite
13 was obtained. Fraction H (30.5 mg) was subjected to normal-phase
silica gel CC (10 g, 1.5 × 15) eluted with CHCl3/MeOH (97:3) to
give metabolites 12 (0.5 mg) and 15 (2.0 mg). Fractions I (55.0 mg)
and J (32.0 mg) on precipitation with MeOH gave metabolites 14 (7.0
mg) and 8 (7.3 mg), respectively.
Cholesta-5,25(27)-diene-1β,3β,7β,14α,26-pentaol-16,22-dione
(2): white, amorphous solid; [α]25D −48 (c 0.1, MeOH); 1H NMR
data (pyridine-d5, 500 MHz) see Table 1;
13C NMR data (pyridine-d5,
125 MHz) see Table 1; HRESIMS (positive ion mode) m/z 499.2653
[M + Na]+ (calcd 499.2671 for C27H40O7Na).
Cholesta-5,25(27)-diene-1β,3β,7α,14α,26-pentaol-16,22-dione
(3): white, amorphous solid; [α]25D −192 (c 0.02, MeOH); 1H NMR
data (pyridine-d5, 500 MHz) see Table 1;
13C NMR data (pyridine-d5,
125 MHz) see Table 1; HRESIMS (positive ion mode) m/z 499.2656
[M + Na]+ (calcd 499.2672 for C27H40O7Na).
Cholesta-5,25(27)-diene-1β,3β,14α,26-tetraol-7,16,22-trione (4):
white, amorphous solid; [α]25D −21 (c 1, MeOH); 1H NMR data
(pyridine-d5, 500 MHz) see Table 1;
13C NMR data (pyridine-d5, 125
MHz) see Table 1; HRESIMS (positive ion mode) m/z 497.2532
(calcd for C27H38O7Na 497.2512).
26-O-Acetylcholesta-5,25(27)-diene-1β,3β,14α,26-tetraol-
7,16,22-trione (5): white, amorphous solid; [α]25D −191 (c 0.03,
MeOH); 1H NMR data (pyridine-d5, 500 MHz) see Table 1;
13C
NMR data (pyridine-d5, 125 MHz) see Table 1; HRESIMS (positive
ion mode) m/z 555.2377 [M + K]+ (calcd for 555.2360 C29H4008K).
Cholesta-4,6,25(27)-triene-1β,14α,26-triol-3,16,22-trione (6):
white, amorphous solid; [α]25D −121 (c 0.1 MeOH); 1H NMR data
(pyridine-d5, 500 MHz) see Table 1;
13C NMR data (pyridine-d5, 125
MHz) see Table 1; HRESIMS (positive ion mode) m/z 479.2403 [M
+ Na]+ (calcd 479.2410 for C27H36O6Na).
18(22)-Epoxyfurosta-5,25(27)-diene-1β,3β,7α,26-tetraol (7):
white, amorphous solid; [α]25D −46 (c 0.1, MeOH); 1H NMR data
(pyridine-d5, 500 MHz) see Table 2;
13C NMR data (pyridine-d5, 125
MHz) see Table 2; HRESIMS (positive ion mode) m/z 483.2784 [M
+ Na]+ (calcd for C27H40O6Na 483.2723).
Spirosta-5,25(27)-diene-1β,3β,7β-triol (8): white, amorphous solid;
[α]25D −126 (c 0.1, MeOH); 1H NMR data (pyridine-d5, 500 MHz)
see Table 2; 13C NMR data (pyridine-d5, 125 MHz) see Table 2;
HRESIMS (positive ion mode) m/z 445.2956 [M + H]+ (calcd for
C27H41O5 445.2954).
Spirosta-5,25(27)-diene-1β,3β,7α,14α-tetraol (9): white, amor-
phous solid; [α]25D −113 (c 0.1, MeOH); 1H NMR data (pyridine-
d5, 500 MHz) see Table 2;
13C NMR data (pyridine-d5, 125 MHz) see
Table 2; HRESIMS (positive ion mode) m/z 483.2733 [M + Na]+
(calcd for C27H40O6Na 483.2723).
Spirosta-5,25(27)-diene-1β,3β,7α,12β,14α-pentaol (10): white,
amorphous solid; [α]25D −68 (c 0.1, MeOH); 1H NMR data
(pyridine-d5, 500 MHz) see Table 2;
13C NMR data (pyridine-d5,
125 MHz) see Table 2; HRESIMS (positive ion mode) m/z 477.2848
[M + H]+ (calcd for C27H41O7 477.2852).
Spirosta-5,25(27)diene-1β,3β,7α,12β-tetraol (11): white, amor-
phous solid; [α]25D −161 (c 0.03, MeOH); 1H NMR data (pyridine-
d5, 500 MHz) see Table 2;
13C NMR data (pyridine-d5, 125 MHz) see
Table 2; HRESIMS (positive ion mode) m/z 461.2904 [M + H]+
(calcd for C27H41O6 461. 2903).
Spirosta-5,25(27)-diene-1β,3β,7α,11α-tetraol (12): white, amor-
phous solid; [α]25D −177 (c 0.03, MeOH); 1H NMR data (pyridine-
d5, 500 MHz) see Table 3;
13C NMR data (pyridine-d5, 125 MHz) see
Table 3; HRESIMS (positive ion mode) m/z 461.2901 [M + H]+
(calcd for C27H41O6 461. 2903).
Spirosta-5,25(27)-diene-1β,3β,8β,14α-tetraol-7-one (13): white,
amorphous solid; [α]25D −75 (c 0.04, MeOH); 1H NMR data
(pyridine-d5, 500 MHz) see Table 3;
13C NMR data (pyridine-d5, 125
MHz) see Table 3; HRESIMS (positive ion mode) m/z 475.2704 [M
+ H]+ (calcd for C27H39O7 475.2696).
Spirosta-5,25(27)-diene-1β,3β,14α-triol-7-one (14): white, amor-
phous solid; [α]25D −212 (c 0.03, MeOH); 1H NMR data (pyridine-
d5, 500 MHz) see Table 3;
13C NMR data (pyridine-d5, 125 MHz) see
Table 3; HRESIMS (positive ion mode) m/z 481.2575 [M + Na]+
(calcd for C27H38O6Na 481.2566).
5β(6)-Epoxyspirosta-5,25(27)diene-1β,3β,7α,14α-tetraol (15):
white, amorphous solid; [α]25D −23 (c 0.1, MeOH); 1H NMR data
(pyridine-d5, 500 MHz) see Table 3;
13C NMR data (pyridine-d5, 125
MHz) see Table 3; HRESIMS (positive ion mode) m/z 483.2728 [M
+ Na]+ (calcd for C27H40O6Na 483.272).
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